Partners‟ complementarity Clause Samples

Partners‟ complementarity. The complementarity of the consortium is based on the diversified expertise that BIOPARTNERS partners‘ possess, covering substantially all the required skills for project‘s successful implementation.  BIOPARTNERS twinning organizations know well each others: The joint development of training modules to build competency and facilitate participation of the DIBBAUG in FP7 will build on already existing expertise or successful collaboration experience. The two twinning partners know well each other and had several joint projects. The DIBBAUG and the University of Murcia has been collaborating since 2000. They had joint projects (in 2001 - 2004. - INTAS-Food, Ref. No: 2000-00727 and in 2004 - 2006 - STCU G-122, in 2007- 2009 - STCU-4329). At present (2011-2012) ▇▇▇▇▇▇▇ and UMU are collaborating in the project STCU #4894- Development of nanotechnology of nanoplant composites and investigation of their antitumor and antioxidant activities. Scientists of ▇▇▇▇▇▇▇ visited the University of Murcia in 2003 and scientists of the University of Murcia visited DIBBAUG twice in 2001 and 2004. The twinning parties have also collaborated for science publications, for ex:  Sadunishvili T., ▇▇▇▇▇▇▇ N., Kvesitadze ▇. ▇▇▇▇▇▇▇▇▇ - ▇▇▇▇▇ ▇. ▇. Thermostability and Storage of Horseradish and Tea Plant Peroxidases. VI International Plant Peroxidase Symposium, Murcia 3-7 July, 289-291, 2002  Omiadze N, ▇▇▇▇▇▇ H., ▇▇▇▇▇▇▇ ▇., ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇., ▇▇▇▇▇ ▇., Akhvlediani ▇., ▇▇▇▇▇▇▇▇ M, ▇▇▇▇▇▇▇▇▇▇▇▇ T., ▇▇▇▇▇▇▇▇▇ - ▇▇▇▇▇ ▇. ▇, ▇▇▇▇▇▇▇▇▇▇ G. Inhibition of apple phenoloxidase and peroxidase by natural phenolics of tea leaves. Advances in Food Sciences, 2004, 26, 1, 26-31.  Alyabyev ▇., ▇▇▇▇▇▇ ▇., ▇▇▇▇▇▇ N., ▇▇▇▇▇▇▇▇▇ ▇., Tribunskih V., ▇▇▇▇▇▇▇ ▇., ▇▇▇▇▇▇▇▇▇▇▇▇ ▇., ▇▇▇▇▇ L., ▇▇▇▇▇▇▇▇▇▇▇▇▇ N., ▇▇▇▇▇▇▇▇▇-▇▇▇▇▇ ▇.▇. The Effect of a Natural Inhibitor Isolated from the Tea Leaf on the Energy Processes in Model Systems. Thermochimica Acta. 2004. V.422. N1-2, pp.109-113. Inno has been already helping DIBBAUG to understand FP7 programme and to strengthen their FP7 skills.  Easy access to Bio-Tech organizations in Georgia and in Europe, and good collaboration experience: UMU works with a large network of European organisations, and DIBBAUG works with a lot of private and public organisations in Georgia and in the Caucasus. Inno works for a consortium of European universities and helped a number of the European research organisations to develop their strategic plans and commercialisation strategies....
View Source

Related to Partners‟ complementarity

  • Condominiums/Planned Unit Developments If the Mortgaged Property is a condominium unit or a planned unit development (other than a de minimis planned unit development) such condominium or planned unit development project such Mortgage Loan was originated in accordance with, and the Mortgaged Property meets the guidelines set forth in the Originator's Underwriting Guidelines;

  • Teams One team for the purposes of the Event shall consist of one Vehicle. Each Vehicle can contain a maximum of three Team Members, provided such Team Members have entered into a Team Entry Agreement with the Company or have otherwise agreed in writing to participate in the Event upon and subject to the Terms of Entry and the Event Rules. For the avoidance of doubt, it is the sole responsibility of each Team to inform themselves of the maximum numbers of persons legally permitted to travel in the Vehicle under Relevant Law. The Company shall provide each Team with the contact details of the Approved Hirer who will be able to provide each Team with a Vehicle for use in the Event, subject to the Team entering into an agreement (the "Borrowing Agreement") with the Hirer outlining the terms of use of the Vehicle. Should the Vehicle not be delivered to the Designated Finish Point by 14:00 local time on 9th January 2025, then the team will be liable for the "Hire Costs" outlined below. Each Vehicle will be of a similar specification to that outlined in Schedule 4 to the Team Entry Agreement. For the avoidance of doubt, the Company shall make no representations or warranties as to the suitability of the Approved Hirer or of the Vehicle for participation in the Event and any rights or warranties which a Team may have or be granted in relation to the Vehicle shall be limited to those contained in the Rental Agreement or implied by any Relevant Law.

  • Safe Operations Notwithstanding any other provision of this Agreement, an NTO may take, or cause to be taken, such action with respect to the operation of its facilities as it deems necessary to maintain Safe Operations. To ensure Safe Operations, the local operating rules of the ITO(s) shall govern the connection and disconnection of generation with NTO transmission facilities. Safe Operations include the application and enforcement of rules, procedures and protocols that are intended to ensure the safety of personnel operating or performing work or tests on transmission facilities.

  • Infrastructure Vulnerability Scanning Supplier will scan its internal environments (e.g., servers, network devices, etc.) related to Deliverables monthly and external environments related to Deliverables weekly. Supplier will have a defined process to address any findings but will ensure that any high-risk vulnerabilities are addressed within 30 days.

  • Development Responsibilities From and after the Effective Date, BMS shall assume sole responsibility for the Development of Compounds and Products in the Field in the Territory during the Term at its own cost and expense (including responsibility for all funding, resourcing and decision-making, subject to Sections 3.3 and 3.4), except with respect to the performance by Ambrx of the Research Program activities assigned to Ambrx pursuant to the Research Plan and as otherwise may be agreed upon by the Parties in writing. BMS, by itself or through its Affiliates and Sublicensees, shall use Diligent Efforts to Develop a Compound or Product in the Field in accordance with the Development Plan for the purpose of obtaining a Regulatory Approval in each Major Market [***]. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Compounds and Products may include sequential implementation of Clinical Trials and/or intervals between Clinical Trials for data interpretation and clinical program planning and approval.